Dr. Reddy's Laboratories Ltd. on Wednesday said it has launched Bortezomib for Injection 3.5 mg/vial, indicated for the treatment of certain types of cancers in adult patients, in the U.S. market.
The company has launched Bortezomib for Injection 3.5 mg/vial, approved by the United States Food and Drug Administration via a new drug application pathway for intravenous use only, Dr. Reddy's Laboratories said in a statement.
-
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
India Could Gain If AI Trade Unwinds, US Midterms May Hurt Markets: Ramesh Damani -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
"We're pleased to bring this product to market for the customers and patients who will benefit from this cost-efficient alternative in the market place," Dr. Reddy's Laboratories North America Generics Chief Executive Officer Marc Kikuchi said.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
This is a great addition to the company's injectable offering in the U.S. market as it continues to augment its portfolio of products in the hospital segment, he added. The company's product is for intravenous use only and is indicated for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, the statement said.
Shares of Dr. Reddy's Laboratories were trading at Rs 2,876.90 per scrip on BSE, up 0.62 percent from its previous close.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
